JS207 (Anti-PD-1/VEGF Bispecific Antibody) Combined With Platinum-based Doublet Chemotherapy in Subjects With Stage II-III Non-small Cell Lung Cancer
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Enrollment
- 76
- Locations
- 1
- Primary Endpoint
- PCR rate
Overview
Brief Summary
This is a phase II clinical study to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of JS207 (anti-PD-1/VEGF bispecific antibody) combined with platinum-based doublet chemotherapy in subjects with stage II-III non-small cell lung cancer. The study consists of 2 cohorts, including treatment-naïve and resectable subjects with stage II-III NSCLC (cohort 1), treatment-naïve and unresectalbe subjects with stage III NSCLC (cohort 2). Subjects in both cohorts will receive 3 cycles of JS207 + platinum-based doublet chemotherapy as neoadjuvant therapy, followed by surgery or definitive chemoradiotherapy, and then adjuvant therapy with JS207 (post-surgery) or consolidation therapy with JS207 (post-chemoradiotherapy).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18 to 75 years at the time of signing the informed consent (inclusive of 18 and 75 years), either gender.
- •Histologically confirmed, previously untreated stage II-III NSCLC (AJCC 8th edition), cTNM stage can be confirmed by PET-CT or pathological biopsy. For suspicious lesions that are suspected by imaging examination, which can lead to changes in TNM stage, including but not limited to contralateral mediastinal lymph nodes and supraclavicular lymph nodes, pathological biopsy verification is strongly recommended.
- •Cohort 1: Subjects with resectable, stage II, IIIA, or IIIB (N2) NSCLC evaluated by MDT.
- •Cohort 2: Subjects with unresectable, stage III NSCLC evaluated by MDT.
- •Total lung function can withstand the proposed lung resection procedure according to the surgeon's evaluation.
- •Subjects without EGFR sensitive mutation, ALK fusion, ROS1 fusion or RET fusion. Subjects with squamous cell carcinoma are not required to undergo genetic testing. The Certificate of Analysis from the local laboratory is acceptable, but the test must be well validated and approved by the inter-laboratory quality assessment or NMPA (if the mutation is negative in blood test, it must be confirmed based on the results from tissue sample); if there is no previous Certificate of Analysis or the previous Certificate of Analysis does not meet the requirements, the sample should be provided for testing.
- •At least 3 unstained tumor tissue sections were available for detection of PD-L1 and other biomarkers. If truly unable to provide tumor tissue samples as required, enrollment was also possible after communication with the sponsor.
- •Function of vital organs meets the requirements.
Exclusion Criteria
- •In the company of the following study disease status:
- •Histopathologically or cytologically confirmed combined components of neuroendocrine tumours (including small cell lung cancer, large cell neuroendocrine carcinoma, etc.) and Pancoast tumor.
- •Tumor encircles important blood vessels or has obvious necrosis and air space, and the investigator considers that it may cause hemorrhage risk.
- •Any clinically significant hemoptysis (≥2.5 ml) or Tumour haemorrhage of any cause within one month before the first use of the study drug.
- •Received any of the following treatments:
- •Previous systemic antitumor therapy for NSCLC (including investigational drugs), such as chemotherapy or immunologically mediated therapy (including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA-4 therapy) and anti-angiogenic therapy (such as anti-VEGF pathway-targeted drugs);
- •Prior radiotherapy to chest;
- •History of significant Haemorrhagic diathesis or severe Disorder coagulation, or Grade ≥3 bleeding event within 6 months prior to the first dose, or current ≥Grade 2 bleeding or factors that are judged by the investigator to be at high risk for bleeding (e.g., active peptic ulcer or Varices oesophageal).
- •Gastrointestinal perforation, intra-abdominal fistula, or intra-abdominal abscess within 6 months prior to the first dose, or current risk factors for perforation/fistula formation of hollow organs as judged by the investigator, such as tumor invasion of the outer layer of hollow organ wall, or active inflammatory bowel disease (including Colitis ulcerative and Crohn's disease), Diverticulitis, Cholecystitis, symptomatic Cholangitis or Appendicitis.
- •Existence of poorly controlled Hypertension, or history of Hypertensive crisis or Hypertensive encephalopathy.
Arms & Interventions
Cohort1：enrolled untreated resectable stage II-III NSCLC patients（JS207）
Preoperative neoadjuvant therapy phase, the receive JS207 + platinum-based double chemotherapyonce every 3 weeks，then perform Surgical treatment，after that，perform postoperative ADJUVANT THERAPY （JS207）
Intervention: Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma (Drug)
Cohort1：enrolled untreated resectable stage II-III NSCLC patients（JS207）
Preoperative neoadjuvant therapy phase, the receive JS207 + platinum-based double chemotherapyonce every 3 weeks，then perform Surgical treatment，after that，perform postoperative ADJUVANT THERAPY （JS207）
Intervention: surgery (Procedure)
Cohort1：enrolled untreated resectable stage II-III NSCLC patients（JS207）
Preoperative neoadjuvant therapy phase, the receive JS207 + platinum-based double chemotherapyonce every 3 weeks，then perform Surgical treatment，after that，perform postoperative ADJUVANT THERAPY （JS207）
Intervention: JS207 (Drug)
Cohort2：enrolled untreated, stage III NSCLC patients（JS207）
Preoperative neoadjuvant therapy phase, the receive JS207 + platinum-based double chemotherapyonce every 3 weeks，then perform Surgical treatment or CRT，after that，perform postoperative ADJUVANT THERAPY （JS207）
Intervention: Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma (Drug)
Cohort2：enrolled untreated, stage III NSCLC patients（JS207）
Preoperative neoadjuvant therapy phase, the receive JS207 + platinum-based double chemotherapyonce every 3 weeks，then perform Surgical treatment or CRT，after that，perform postoperative ADJUVANT THERAPY （JS207）
Intervention: surgery (Procedure)
Cohort2：enrolled untreated, stage III NSCLC patients（JS207）
Preoperative neoadjuvant therapy phase, the receive JS207 + platinum-based double chemotherapyonce every 3 weeks，then perform Surgical treatment or CRT，after that，perform postoperative ADJUVANT THERAPY （JS207）
Intervention: Radiochemotherapy (Radiation)
Cohort2：enrolled untreated, stage III NSCLC patients（JS207）
Preoperative neoadjuvant therapy phase, the receive JS207 + platinum-based double chemotherapyonce every 3 weeks，then perform Surgical treatment or CRT，after that，perform postoperative ADJUVANT THERAPY （JS207）
Intervention: JS207 (Drug)
Outcomes
Primary Outcomes
PCR rate
Time Frame: 2 years
To evaluate the pathologic complete response rate (pCR rate) of JS207 combined with platinum-based doublet chemotherapy in subjects with resectable stage II-III NSCLC and subjects with uresectable stage III NSCLC.
Secondary Outcomes
- MPR rate(2 years)
- ORR(2 years)
- DCR(2 years)
- OS(2 years)
- EFS(2 years)